Actually, enrollment was halted much earlier, and the trial was never conducted in the manner of a serious pivotal study.
The “low-volume” formulation of Copaxone was (IMO) an evergreening gimmick to impress Wall Street that was no longer needed once Teva settled on the thrice-weekly alternative. The low-volume formulation never had a bona fide chance of being brought to market, as I said two years ago in #msg-59788384.
Market Data 
Markets 
AI
